Celltrion Pharm Inc (068760) — Capital Reinvestment Ratio
Celltrion Pharm Inc (068760) has a Capital Reinvestment Ratio of 0.10x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩23.44 Billion) in capital expenditures (₩2.27 Billion). Check tangible net worth ratio of Celltrion Pharm Inc to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Celltrion Pharm Inc Capital Reinvestment Ratio (2014–2024)
This chart tracks Celltrion Pharm Inc's Capital Reinvestment Ratio across 8 annual periods. For the full cash flow conversion analysis, see Celltrion Pharm Inc cash flow conversion.
Annual Capital Reinvestment Ratio for Celltrion Pharm Inc (2014–2024)
Year-by-year Capital Reinvestment Ratio for Celltrion Pharm Inc from 2014 to 2024. See free cash flow generation of Celltrion Pharm Inc to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.11x | ₩56.59 Billion | ₩5.98 Billion | ▼ -86.6% |
| 2023 | 0.79x | ₩8.76 Billion | ₩6.90 Billion | ▲ +487.0% |
| 2021 | 0.13x | ₩93.15 Billion | ₩12.50 Billion | ▼ -88.4% |
| 2020 | 1.16x | ₩36.25 Billion | ₩41.98 Billion | ▲ +5.8% |
| 2019 | 1.09x | ₩27.85 Billion | ₩30.49 Billion | ▲ +117.4% |
| 2018 | 0.50x | ₩14.31 Billion | ₩7.21 Billion | ▼ -85.4% |
| 2015 | 3.44x | ₩13.36 Billion | ₩45.97 Billion | ▲ +127.8% |
| 2014 | 1.51x | ₩17.33 Billion | ₩26.16 Billion | — |